Alopecia Areata and Ritlecitinib: Unraveling Response Trajectories

May 2025 in “ Journal of the European Academy of Dermatology and Venereology ”

Julien Sénéschal

ritlecitinib JAK3/TEC family kinase inhibitor alopecia areata SALT score baricitinib JAK inhibitors

From the encyclopedia

autoimmune disorder causing patchy hair loss

JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

Studysummary This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study investigates the long-term response patterns to ritlecitinib, a JAK3/TEC family kinase inhibitor, in treating alopecia areata (AA). It analyzes data from the ALLEGRO-2b/3 and ALLEGRO-LT trials, categorizing patients into six responder groups based on the Severity of Alopecia Tool (SALT) score. The study found that 45.5% of patients achieved a SALT score ≤ 20, with 46.0% attaining complete hair regrowth, and 93.1% of responders maintained their response over 24 months. The analysis highlights that less severe and shorter-duration AA cases respond better, with female patients more likely to experience favorable outcomes. The study suggests that initiating treatment before severe AA onset may yield better results and calls for further research to optimize management, including exploring combination therapies and alternative JAK inhibitors.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata

December 2024 in “Clinical and Experimental Dermatology”

In this study, researchers found that ritlecitinib, a JAK3/TEC inhibitor, significantly improves hair regrowth, quality of life, and psychological well-being in patients with severe alopecia areata who had inadequate or no response to baricitinib, a JAK1/2 inhibitor.

Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

September 2023 in “British Journal of Dermatology”

In this study, researchers identified subgroups of patients with severe alopecia areata treated with baricitinib who experienced early, gradual, or late hair regrowth, finding that response was influenced by baseline disease severity and duration of hair loss.

Major Improvement of Very Severe Alopecia Areata in Patients Treated With the Combination of Baricitinib and Low Doses of Corticosteroids: An Eight-Case Series

research Major Improvement of Very Severe Alopecia Areata in Patients Treated With the Combination of Baricitinib and Low Doses of Corticosteroids: An Eight-Case Series

July 2023 in “Clinical and Experimental Dermatology”

In this study, combining baricitinib and prednisone effectively achieved complete hair regrowth in seven out of eight women with very severe alopecia areata, contrasting with less effective results from each drug used alone.